Glowing dye to spot lung cancer during bronchoscopy
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new way to see cancer during a bronchoscopy. A special dye (bevacizumab with a fluorescent marker) is used to make tumors glow under a special light, which may help doctors find and remove cancer more precisely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You have a lung nodule (spot or growth) that is likely cancerous
- You are able to have a bronchoscopy (a tube placed in your airway to get a tissue sample)
- You have not had an allergic reaction to bevacizumab before
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study uses special drug dyes (bevacizumab and cetuximab, each tagged for imaging) during an esophagus scope to help doctors find very early abnormal cells, like low- or high-grade pre-cancer and superficial cancer. If you qualify, the goal is earlier detection and better targeting during diagnosis and treatment.
This study tests a special dye attached to durvalumab (a cancer drug) to see if it can light up tumors in the lungs during a bronchoscopy. It will help doctors see if the drug reaches the cancer cells and may guide future treatments.
This study looks for blood test markers that may predict who survives at 6 months after starting bevacizumab for glioblastoma that has come back. It does not aim to cure the cancer by itself, but to improve doctors’ ability to choose the most helpful treatment plan.
This trial tests a new targeted therapy (DZD9008) combined with a drug that blocks blood vessel growth (bevacizumab) for people with a specific type of advanced lung cancer (EGFR mutation). The goal is to see if this combination works better than current treatments.
This trial compares a combination of anti-angiogenics (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) against Avastin-based treatment in people with advanced non-small cell lung cancer. It aims to find out whether the study treatment is safer and works better for shrinking tumors and improving outcomes.
This Phase 3 study compares two treatment plans for people with metastatic colorectal cancer that got worse or caused side effects after first chemotherapy. It looks at whether adding bevacizumab (a medicine that targets blood vessels feeding tumors) improves outcomes versus using a different chemotherapy approach.
Hear when a new Lung Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.